Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
This study evaluated a difficult-to-treat Crohn's disease patient population
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Subscribe To Our Newsletter & Stay Updated